The mechanism of action of specific noradrenaline re-uptake inhibitors

Depression is associated with reduced levels of the monoamines in the brain, such as noradrenaline. The selective noradrenaline re-uptake inhibitors (NRIs) are thought to restore the levels of noradrenaline in the synaptic cleft by binding at the noradrenaline re-uptake transporter preventing the re-uptake and subsequent degradation of noradrenaline. This re-uptake blockade leads to the accumulation of noradrenaline in the synaptic cleft and the concentration of noradrenaline returns to within the normal range. This action of NRIs is though to contribute to the alleviation of the symptoms of depression. In the presence of the NRI, small amounts of noradrenaline continue to be degraded in the synaptic cleft.

  1. Noradrenergic transmission. In: Pharmacology, 4th edition. Rang HP, Dale MM and Ritter JM. Edinburgh, UK: Harcourt Publishers Ltd, 2001:139–163.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country